marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Yumanity Therapeutics Balance Sheet 2011-2024 | YMTX
Annual Balance Sheet Yumanity Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.08 M | -12.2 M | -10.3 M | -4.19 M | 1.2 M | - | - | - | - | - | - | - | - |
Long Term Debt |
159 K | 83 K | 90 K | 2.89 M | 14.5 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
547 K | 843 K | 737 K | 4.47 M | 1.15 M | 1.06 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 105 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
7.07 M | 11.5 M | 14.4 M | 30.9 M | 10.3 M | 8.6 M | 10.3 M | 8.75 M | - | - | - | - | - |
Total Liabilities |
7.22 M | 12.9 M | 25.3 M | 58.6 M | 110 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 442 K | 1.04 M | 8.1 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-166 M | -152 M | -88.3 M | - | -97 M | - | - | - | - | - | - | - | - |
Total Assets |
10.3 M | 17.4 M | 13.4 M | 115 M | 17.6 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
5.78 M | 13.1 M | 11.1 M | 11.5 M | 25 M | 28.8 M | 29.7 M | 18.6 M | 13.8 M | 8.79 M | - | - | - |
Book Value |
3.06 M | 4.57 M | -11.9 M | 56.2 M | -91.9 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
2.89 M | 4.42 M | -12.1 M | -21.5 M | -91.9 M | 114 M | 68.8 M | 81.5 M | -108 M | -95.1 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Yumanity Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 150 K | - | 164 K | 400 K | 779 K | 83 K | - | - | - | 7.36 M | 8.74 M | 10.1 M | 11.4 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 14.5 M | 12.3 M | 12 M | 12 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
11.8 M | 9.38 M | 8.68 M | 7.22 M | 7.82 M | 9.89 M | 13.1 M | 12.9 M | 4.1 M | - | 19.9 M | 39.4 M | 37.4 M | 40.1 M | 43.4 M | 58.6 M | 58.6 M | 58.6 M | 58.6 M | 19.8 M | 22.3 M | 22.3 M | 22.3 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 9.91 M | 9.91 M | 9.91 M | 9.91 M | 9.68 M | 9.68 M | 9.68 M | 9.68 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | 161 K | 442 K | 979 K | - | 4.04 M | 5.06 M | 823 K | 2.46 M | 4.57 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | - | - | - | - | - | - | - | - | 1.11 M | 1.75 M | 2.23 M | 2.42 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 4.08 M | 4.08 M | 4.08 M | 4.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-180 M | -179 M | -176 M | -166 M | -163 M | -158 M | -158 M | -152 M | -209 M | - | -201 M | -187 M | -177 M | -167 M | -156 M | -148 M | -148 M | -148 M | -148 M | -97 M | -337 M | -337 M | -337 M | -278 M | -278 M | -278 M | -278 M | -217 M | -217 M | -217 M | -217 M | -157 M | -157 M | -157 M | -157 M | -120 M | -120 M | -120 M | -120 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.22 M | 1.4 M | 2.43 M | 10.3 M | 10.7 M | 17.5 M | 13 M | 17.4 M | 9.58 M | - | 31.6 M | 62.9 M | 69.8 M | 81.3 M | 92.3 M | 115 M | 115 M | 115 M | 115 M | 17.6 M | 84.7 M | 84.7 M | 84.7 M | 136 M | 136 M | 136 M | 136 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | 91.1 M | 91.1 M | 91.1 M | 91.1 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
1.95 M | 900 K | 1.77 M | 5.78 M | 7.56 M | 7.77 M | 9.24 M | 13.1 M | 2.81 M | 4.47 M | 4.24 M | 35.1 M | 43.5 M | 47.3 M | 52.1 M | 80.8 M | 80.8 M | 80.8 M | 80.8 M | 14 M | 25 M | 25 M | 25 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 8.79 M | - | - | - | 2.59 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-9.55 M | -7.98 M | -6.24 M | 3.06 M | 2.89 M | 7.61 M | -56 K | 4.57 M | 5.48 M | - | 11.7 M | 23.5 M | 32.5 M | 41.1 M | 48.9 M | 56.2 M | 56.2 M | 56.2 M | 56.2 M | -2.2 M | 62.4 M | 62.4 M | 62.4 M | 114 M | 114 M | 114 M | 114 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 4.19 M | 4.19 M | 4.19 M | 4.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-9.7 M | -8.14 M | -6.4 M | 2.89 M | 2.89 M | 7.61 M | -56 K | 4.42 M | -22.1 M | -19.3 M | -16.3 M | 23.5 M | 32.5 M | 41.1 M | 48.9 M | 56.2 M | 56.2 M | 56.2 M | 56.2 M | -91.9 M | 62.4 M | 62.4 M | 62.4 M | -62.2 M | 114 M | 114 M | 114 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | -108 M | -108 M | -108 M | -108 M | -95.1 M | - | - | - | -73.7 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency